Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 682Neoplasms 594Carcinoma, Non-Small-Cell Lung 293Colorectal Neoplasms 292Prostatic Neoplasms 284Lung Neoplasms 224Melanoma 161Multiple Myeloma 151Neoplasm Metastasis 146Pancreatic Neoplasms 143Head and Neck Neoplasms 143Ovarian Neoplasms 136Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 123Colonic Neoplasms 114Brain Neoplasms 113Squamous Cell Carcinoma of Head and Neck 111Uterine Cervical Neoplasms 109Stomach Neoplasms 106Recurrence 101Lymphoma 101Glioblastoma 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 83Lymphoma, Non-Hodgkin 82Hematologic Neoplasms 80Urinary Bladder Neoplasms 78Lymphoma, Follicular 78Glioma 77Parkinson Disease 4, Autosomal Dominant Lewy Body 74Sarcoma 72

Interventions

Lenalidomide 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphomatoid Papulosis × 1 year × Clear all
NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡